CR20110070A - Notch fixing agents and antagonists and methods for their use - Google Patents

Notch fixing agents and antagonists and methods for their use

Info

Publication number
CR20110070A
CR20110070A CR20110070A CR20110070A CR20110070A CR 20110070 A CR20110070 A CR 20110070A CR 20110070 A CR20110070 A CR 20110070A CR 20110070 A CR20110070 A CR 20110070A CR 20110070 A CR20110070 A CR 20110070A
Authority
CR
Costa Rica
Prior art keywords
antagonists
methods
notch
fixing agents
notch fixing
Prior art date
Application number
CR20110070A
Other languages
Spanish (es)
Inventor
Austin L Gurney
Timothy Charles Hoey
Van Der Horst Edward Thein Htun
Aaron Ken Sato
Yuan Ching Liu
Maureen Fitch Bruhns
John A Lewicki
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Priority to CR20110070A priority Critical patent/CR20110070A/en
Publication of CR20110070A publication Critical patent/CR20110070A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente invento se relaciona con agentes fijadores de Notch y antagonistas de la proteína Notch y métodos para el uso de los agentes y/o antagonistas para el tratamiento de enfermedades como el cáncer. El presente invento suministra anticuerpos los cuales se fijan de manera específica a una región no fijadora de ligandos del dominio extracelular de uno o más receptores Notch humanos, como Notch2 y/o Notch3, e inhiben el crecimiento tumoral.The present invention relates to Notch fixing agents and Notch protein antagonists and methods for the use of agents and / or antagonists for the treatment of diseases such as cancer. The present invention provides antibodies which specifically bind to a non-binding region of extracellular domain ligands of one or more human Notch receptors, such as Notch2 and / or Notch3, and inhibit tumor growth.

CR20110070A 2011-02-07 2011-02-07 Notch fixing agents and antagonists and methods for their use CR20110070A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CR20110070A CR20110070A (en) 2011-02-07 2011-02-07 Notch fixing agents and antagonists and methods for their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CR20110070A CR20110070A (en) 2011-02-07 2011-02-07 Notch fixing agents and antagonists and methods for their use

Publications (1)

Publication Number Publication Date
CR20110070A true CR20110070A (en) 2011-07-11

Family

ID=44996361

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110070A CR20110070A (en) 2011-02-07 2011-02-07 Notch fixing agents and antagonists and methods for their use

Country Status (1)

Country Link
CR (1) CR20110070A (en)

Similar Documents

Publication Publication Date Title
DOP2011000004A (en) NOTCH FIXING AGENTS AND ANTAGONISTS AND METHODS FOR THE USE OF THE SAME
MX2016012094A (en) COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT.
HRP20182202T1 (en) USE OF CHAMBER MODIFIED BY CHIMERA ANTIGEN RECEPTOR FOR CANCER TREATMENT
CR20140146A (en) ANTI-BODIES ANTI-CD134 (OX40) AND USES OF THE SAME
GEAP202114132A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CL2016002359A1 (en) Antibodies that bind to human epidermal growth receptor (anti-egfr) and anti-egfr antibody and drug conjugates
UA107827C2 (en) ANTIBODY TO CD40
CR20130126A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE OF THE SAME
BR112017006825A2 (en) antibodies to glucocorticoid-induced tumor necrosis factor receptor (gitr) and their methods of use
EA201490778A1 (en) ANTIBODIES AGAINST HtrA1 AND METHODS OF APPLICATION
EA201500314A1 (en) DOSAGE FORMS OF ENZALUTAMIDE
EA201491357A1 (en) ANTI-LRP5 ANTIBODIES AND METHODS OF THEIR APPLICATION
MX373097B (en) Bispecific anti-hapten/anti-blood-brain barrier receptor antibodies, their complexes, and their use as carriers across the blood-brain barrier.
MX377844B (en) Antibodies to the glucocorticoid-induced tumor necrosis factor receptor (GITR)-related protein and their methods of use.
GT201300118A (en) ESPIRO-OXINDOL MDM2 ANTAGONISTS
HRP20220897T8 (en) COMBINATION THERAPY INCLUDING ANTI-CLAUDIN 18.2 ANTIBODIES FOR THE TREATMENT OF CANCER
MX2013013226A (en) c-KIT ANTIBODIES AND USES THEREOF.
PE20150360A1 (en) HUMAN R-SPONDINE PROTEIN BINDING AGENTS (RSP03) AND USES OF THEM
BR112016018891A2 (en) anti-dll3 antibodies and drug conjugates for use in melanoma
MX391175B (en) PEPTIDOMIMETIC MACROCYCLES.
MX370597B (en) USE OF A BI-SPECIFIC ANTIBODY FOR DLL3 AND CD3 IN THE TREATMENT AND PROPHYLAXIS OF CANCER.
EA201391248A1 (en) BISPECIFIC BINDING AGENTS
EA201400178A1 (en) BREAST CANCER TREATMENT
CR20130517A (en) COMBINED TREATMENTS FOR MALIGNAS HEMATOLOGICAL NEOPLASIAS
BR112018000254A2 (en) pde9 inhibitors with imidazotriazinone main chain and imidazopyrazinone main chain for the treatment of peripheral diseases